The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.
 
Kathryn Finch Mileham
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Merck
Research Funding - Celgene
 
Suanna Steeby Bruinooge
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; Blueprint Genetics; Celgene; Daiichi Sankyo/Astra Zeneca; Genentech; Lilly; Merck; Shionogi
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Alicia L. Patrick
No Relationships to Disclose
 
Christiana Davis
No Relationships to Disclose
 
Daniel Mesenhowski
No Relationships to Disclose
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)
 
Eric J. Clayton
Employment - HCA Healthcare; US Oncology
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - US Oncology
Travel, Accommodations, Expenses - US Oncology
 
David Michael Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; AZTherapies; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Janssen Oncology; Jazz Pharmaceuticals; McGivney Global Advisors; Merck; Mirati Therapeutics; Pfizer; Sanofi/Regeneron; Seagen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sue Moore
No Relationships to Disclose
 
Abdul-Rahman Jazieh
Research Funding - AstraZeneca; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Ronald C. Chen
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Bayer; Blue Earth Diagnostics; Genentech; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
 
Melinda Kaltenbaugh
No Relationships to Disclose
 
Jen Hanley Williams
No Relationships to Disclose
 
Richard L. Schilsky
Consulting or Advisory Role - Cellworks; Scandion Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Liz Garrett-Mayer
Consulting or Advisory Role - Deciphera; TYME